Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Enterprise Value: 2017-2025

Historic Enterprise Value for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $2.8 billion.

  • Crinetics Pharmaceuticals' Enterprise Value fell 12.30% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.3 billion, marking a year-over-year decrease of 470.40%. This contributed to the annual value of $3.4 billion for FY2024, which is 86.45% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Enterprise Value is $2.8 billion, which was up 704.92% from $351.6 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Enterprise Value registered a high of $3.4 billion during Q4 2024, and its lowest value of $351.6 million during Q2 2025.
  • Its 3-year average for Enterprise Value is $1.8 billion, with a median of $1.8 billion in 2023.
  • In the last 5 years, Crinetics Pharmaceuticals' Enterprise Value soared by 313.73% in 2024 and then crashed by 86.83% in 2025.
  • Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' Enterprise Value stood at $1.0 billion in 2021, then tumbled by 36.08% to $649.0 million in 2022, then soared by 179.95% to $1.8 billion in 2023, then surged by 86.45% to $3.4 billion in 2024, then fell by 12.30% to $2.8 billion in 2025.
  • Its last three reported values are $2.8 billion in Q3 2025, $351.6 million for Q2 2025, and $641.3 million during Q1 2025.